Trial Profile

A phase 2/3 clinical study comparing JS207 to nivolumab for the neoadjuvant treatment of patients with stage II/III, resectable, actionable genomic aberration (AGA)-negative, non-small cell lung cancer

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 25 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Nov 2025 New trial record
16 Oct 2025 According to Junshi Biosciences media release, the company announced that professor Yilong WU from Guangdong Provincial People's Hospital will be the principal investigator.
16 Oct 2025 According to Junshi Biosciences media release, the company announced that the investigational new drug (IND) application for , phase 2/3 clinical study has been approved by the U.S. Food and Drug Administration.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com